Prognostic Impact of Additional Extended Surgical Procedures in Advanced-Stage Primary Ovarian Cancer

被引:49
作者
Kommoss, S. [1 ]
Rochon, J. [2 ]
Harter, P. [1 ]
Heitz, F. [1 ]
Grabowski, J. P. [1 ]
Ewald-Riegler, N. [1 ]
Haberstroh, M. [1 ]
Neunhoeffer, T. [1 ]
Barinoff, J. [1 ]
Gomez, R. [1 ]
Traut, A. [1 ]
du Bois, A. [1 ]
机构
[1] Dr Horst Schmidt Klin, Dept Gynecol & Gynecol Oncol, Wiesbaden, Germany
[2] Univ Hosp Regensburg, Ctr Clin Studies, Regensburg, Germany
关键词
PRIMARY CYTOREDUCTIVE SURGERY; SURVIVAL; CARCINOMA; RESECTION; CRITIQUE; DISEASE;
D O I
10.1245/s10434-009-0787-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Treatment of advanced-stage ovarian carcinoma includes radical cytoreductive surgery, which aims at removing all visible tumor tissue followed by platinum and paclitaxel chemotherapy. Complete tumor resection may require extended surgical procedures. This paper reports on the prognostic impact of extensive surgery and surgical morbidity in patients with advanced-stage ovarian carcinoma. Patients with ovarian carcinoma [F,d,ration Internationale de Gyn,cologie et d'Obst,trique (FIGO) stage IIIB-IV] undergoing primary surgery in our tertiary gynecologic oncology unit between 1997 and 2007 were eligible for this study. The impact of established prognostic factors and the interaction with extent of surgical procedures on survival were assessed. A total of 267 patients aged between 29 and 88 years (median 64 years) were eligible for this study. Overall survival time was improved in patients who underwent complete tumor resection [hazard ratio (HR) 3.61 (1.91-6.61), P < 0.001]. No significant survival difference was observed between completely operated patients in whom extended or standard surgical procedures were applied [HR 1.37 (0.70-2.69), P = 0.358], and severe surgical complications were found to be equally distributed between the two patient groups. Our results may encourage the application of extended surgical procedures in patients who would otherwise be rendered incompletely debulked after primary cytoreduction. We could demonstrate an impact of complete tumor resection on patient prognosis and this was not traded off for extensive additional surgical morbidity.
引用
收藏
页码:279 / 286
页数:8
相关论文
共 29 条
[1]   Aggressive surgical effort and improved survival in advanced-stage ovarian cancer [J].
Aletti, GD ;
Dowdy, SC ;
Gostout, BS ;
Jones, MB ;
Stanhope, CR ;
Wilson, TO ;
Podratz, KC ;
Cliby, WA .
OBSTETRICS AND GYNECOLOGY, 2006, 107 (01) :77-85
[2]   Aggressive and complex surgery for advanced ovarian cancer: An economic analysis [J].
Aletti, Giovanni D. ;
Podratz, Karl C. ;
Moriarty, James R. ;
Cliby, William A. ;
Long, Kirsten Hall .
GYNECOLOGIC ONCOLOGY, 2009, 112 (01) :16-21
[3]  
Armitage P., 2001, STAT METHODS MED RES, V4th
[4]   Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer [J].
Bristow, RE ;
Montz, FJ ;
Lagasse, LD ;
Leuchter, RS ;
Karlan, BY .
GYNECOLOGIC ONCOLOGY, 1999, 72 (03) :278-287
[5]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[6]   Splenectomy and surgical cytoreduction for ovarian cancer [J].
Chen, LM ;
Leuchter, RS ;
Lagasse, LD ;
Karlan, BY .
GYNECOLOGIC ONCOLOGY, 2000, 77 (03) :362-368
[7]   What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? [J].
Chi, D. S. ;
Eisenhauer, E. L. ;
Lang, J. ;
Huh, J. ;
Haddad, L. ;
Abu-Rustum, N. R. ;
Sonoda, Y. ;
Levine, D. A. ;
Hensley, M. ;
Barakat, R. R. .
GYNECOLOGIC ONCOLOGY, 2006, 103 (02) :559-564
[8]   Critique of surgical cytoreduction in advanced ovarian cancer [J].
Covens, AL .
GYNECOLOGIC ONCOLOGY, 2000, 78 (03) :269-274
[9]  
COX DR, 1972, J R STAT SOC B, V34, P187
[10]   2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) [J].
du Bois, A ;
Quinn, M ;
Thigpen, T ;
Vermorken, J ;
Avall-Lundqvist, E ;
Bookman, M ;
Bowtell, D ;
Brady, M ;
Casado, A ;
Cervantes, A ;
Eisenhauer, E ;
Friedlaender, M ;
Fujiwara, K ;
Grenman, S ;
Guastalla, JP ;
Harper, P ;
Hogberg, T ;
Kaye, S ;
Kitchener, H ;
Kristensen, G ;
Mannel, R ;
Meier, W ;
Miller, B ;
Neijt, JP ;
Oza, A ;
Ozols, R ;
Parmar, M ;
Pecorelli, S ;
Pfisterer, J ;
Poveda, A ;
Provencher, D ;
Pujade-Lauraine, E ;
Randall, M ;
Rochon, J ;
Rustin, G ;
Sagae, S ;
Stehman, F ;
Stuart, G ;
Trimble, E ;
Vasey, P ;
Vergote, I ;
Verheijen, R ;
Wagner, U .
ANNALS OF ONCOLOGY, 2005, 16 :7-12